Many venture industry observers have wondered whether Andreessen Horowitz, a firm that manages $45 billion, has its sights on ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

Tevogen Bio Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech dev ...

JPM25: Amid Samsung Bio's rapid expansion ... Amid all the dealmaking chatter at this week's J.P. Morgan Healthcare Conference, China was a frequent topic of conversation. At Roche, the company ...

Year-over-year BioSpace data shows there were fewer job postings live on the website in the fourth quarter of 2024, and the ...

We recently published a list of 10 Best Mid-Cap Growth Stocks to Buy According to Analysts. In this article, we are going to ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode and the call will ...

ABL Bio, which is developing new drugs based on a dual antibody ... Lee said, “During a meeting held during the JP Morgan Healthcare Conference (JPM 2025) this month, global big pharmaceutical ...

Bengaluru’s Aecoz, owned by Dhanvita Sathyanand, Srinidhi Rajaram, and Bharath Sathyanand, is proving that sustainable ...

was you have to be a clinical-asset company (to get funding),” said Jodi Cook, president and CEO of Skylark Bio ... churn of M&A news around the J.P. Morgan Healthcare Conference last ...

With another JP Morgan in the rearview mirror ... Andrew Obershain, CEO of bluebird bio, said as much on stage. A year before the FDA approved his company’s gene therapy for sickle cell ...